Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS
Sign Up to like & getrecommendations! Published in 2017 at "Supportive Care in Cancer"
DOI: 10.1007/s00520-017-3853-y
Abstract: PurposeSeveral patients with advanced cancer suffer from breakthrough cancer pain (BTcP). BTcP is pain exacerbation despite opioid baseline therapy. Fentanyl buccal tablet (FBT) is a rapid-onset opioid for the treatment of BTcP. The aim of… read more here.
Keywords: btcp; study; breakthrough cancer; fbt ... See more keywords
Abstract 448: Predicting Blood Pressure Response to Fluid Bolus Therapy Using Neural Networks with Clinical Interpretability
Sign Up to like & getrecommendations! Published in 2019 at "Circulation Research"
DOI: 10.1161/res.125.suppl_1.448
Abstract: Background: Fluid bolus therapy (FBT), the rapid infusion of fluid, has been recommended as the primary-line treatment for acute hypotensive episode (AHE) that occurs in about 41% of patients in ICU. However, previous studies have… read more here.
Keywords: fluid; fbt; blood; clinical interpretability ... See more keywords
Predicting tolerability of high-dose fentanyl buccal tablets in cancer patients
Sign Up to like & getrecommendations! Published in 2022 at "PLOS ONE"
DOI: 10.1371/journal.pone.0280212
Abstract: Background & aims Fentanyl buccal tablets (FBTs) are a rapid-onset opioid indicated for breakthrough cancer pain (BTcP) and FBT titration is needed to optimize BTcP management. We aimed to predict which patients could tolerate a… read more here.
Keywords: dose; dose fbt; tolerance; high dose ... See more keywords